Clinical Trials: Knee Osteoarthritis

This randomized, double-blind, placebo-controlled, multi-center study of 166 people took place over 12 weeks, and was led by Professor Piet Geusens of the Biomedical Research Institute at University Hasselt, Belgium. It was co-authored by K. Pavelka (Institute of Rheumatology, Prague); J. Rovensky (National Institute of Rheumatic Diseases, Slovakia); J. Vanhoof (ReumaClinic, Belgium); N. Demeester and M. Calomme (Research & Development, Bio Minerals, Belgium); and D. Vanden Berghe (University of Antwerp, Belgium). The study was peer-reviewed and published in the journal BMC Musculoskeletal Disorders in 2017.

The research aimed to study the efficacy of ch-OSA® on symptomatic osteoarthritis of the knee.

What we found

Researchers found a significant improvement in men taking ch-OSA® compared to men in the placebo group. After 12 weeks, men taking ch-OSA® reported:

  • 26% less knee discomfort than men in the placebo group
  • 35% less knee stiffness than men in the placebo group
  • 25% better daily function than men in the placebo group

Summary

The improvement in cartilage degradation was also markedly better for men taking ch-OSA®. Biochemical markers of collagen degradation in the blood and urine were significantly lowered. After 12 weeks, researchers found that men taking ch-OSA® had:

  • 25% less CTX-II (C-telopeptide fragments of collagen type II) than men in the placebo group
  • 19% less COMP (cartilage oligomeric matrix protein) than men in the placebo group

Participants

The participants were 166 people (120 women and 46 men); between the ages of 50 and 75, with clear symptoms of cartilage loss in the knee.

Clinical Trials: Knee Osteoarthritis

Figure 1: The reported discomfort, stiffness, and difficulty performing daily functions of men with knee osteoarthritis; men who took ch-OSA® versus men in the control group. WOMAC is a widely-used and validated self-assessment measurement for how joint health impacts people.

Clinical Trials: Knee Osteoarthritis

Figure 2: The presence of biochemical markers of cartilage degradation in men who took ch-OSA® versus men in the control group.

Conclusion

The researchers believe the observed improvements in joint discomfort and mobility are due to the positive effects of ch-OSA® on collagen in cartilage, ligaments, tendons, and bone.

< script > ( function ( ) {Grin = window .Grin || ( window .Grin = []); var s = document .createElement( 'script' );s.type = 'text/javascript' ;s.async = true ;s.src = ' [https://d38xvr37kwwhcm.cloudfront.net/js/grin-sdk.js' ; var ](https://d38xvr37kwwhcm.cloudfront.net/js/grin-sdk.js';var) x = document .getElementsByTagName( 'script' )[ 0 ];x.parentNode.insertBefore(s, x);})();